Abstract
Dual site antibody-base immunoassays are commonly used in clinical laboratories to quantify the CT serum concentrations as a specific and sensitive marker of medullary thyroid carcinoma (MTC). Heterophile antibodies can interfere with these assays, however, and cause erroneous results. In order to avoid this interference, immobilized and conjugated antibodies from two different animal species or immunoreactive antibody fragments, as well as the addition of non-immune globulins, are generally included among the assay reagents. We describe the case of a 73-year-old man affected by a multinodular goiter, who showed high basal CT plasma levels as measured by a monoclonal antibody based IRMA. The finding of negative results for the presence of MTC at fine needle aspiration (FNA) and the mild increase observed in plasma CT during a pentagastrin (Pg) stimulation test, suggested that the high CT levels might depend on a cross-reaction with heterophilic antibodies. In fact, after the addition of the heterophilic blocking tube (HBT) to each specimen, the CT levels markedly decreased by more than 80% (average decrease±SE= 87.6±2.668%). Such a decrease strongly suggests that in our case the routinely used F(ab’)2 fragments were unable to eliminate all of the interference and that the elevated serum CT levels might have been caused by human heterophilic antibodies. In conclusion, these results indicate a novel cause of CT false positivity, suggesting that high serum CT levels, when combined with a slight increase during Pg stimulation, should be critically interpreted in view of the possible presence of heterophilic antibodies in the specimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barbot N., Calmettes C., Schuffenecker I., Saint-Andre J.P., Franc B., Rohmer V., Jallet P., Bigorgne J.C. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1994, 78: 114–120.
Marsh D.J., McDowall D., Hyland V.J., Andrew S.D., Schnitzler M., Gaskin E.L., Nevell D.F., Diamond T., Delbridge L., Clifton-Bligh P., Robinson B.G. The identification of false positive reponses to the pentagastrin stimulation test in RET mutation negative members f MEN 2A families. Clin. Endocrinol. (Oxf.) 1996, 44: 213–220.
Niccoli P., Wion-Barbot N., Caron P., Henry J.F., De Micco C., Saint-Andre J.P, Bigorgne J.C., Modigliani E., Conte-Devolx B. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J. Clin. Endocrinol. Metab. 1997, 82: 338–341.
Kuroki M., Matsumoto Y., Arakawa F., Haruno M., Murakami M., Kuwahara M., Ozaki H., Senba T., Matsuoka Y. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J. Immunol. Methods 1995, 180: 81–91.
Levinson S.S. Antibody multispecificity in immunoassay interference. Clin. Biochem. 1992, 25: 77–87.
Ward G., Mckinnon L., Badrick T., Hickman P.E. Heterophilic antibodies remain a problem for the immunoassay laboratory. Am. J. Clin. Pathol. 1997, 108: 417–421.
Sosolik R., Hitchcoch C.L., Becker W.J. Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Am. J. Clin. Pathol. 1996, 107: 506–510.
Liendo C., Ghali J.K., Steven W.G. A new interference in some digoxin assays: antimurine heterophilic antibodies. Clin. Pharmacol. Ther. 1996, 60: 593–598.
Benoist J.F., Orbach D., Biou D. False increase in C-reactive protein attributable to heterophilic antibodies in two renal transplant patients treated with rabbit antilymphocite globulin. Clin. Chem. 1998, 44: 1980–1985.
Kairemo K.J.A., Kahn J.A., Taipale P.J. Monoclonal gammopathy may disturb oestradiol measurement in the treatment and monitoring of in vitro fertilization. Hum. Reprod. 1999, 14: 2724–2726.
Pacini F., Fontanelli M., Fugazzola L., Elisei R., Romei C., Di Coscio G., Miccoli P., Pinchera A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1994, 78: 826–829.
Vierhapper H., Raber W., Bieglmayer C., Kaserer K., Weinhäusl A., Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J. Clin. Endocrinol. Metab. 1997, 82: 1589–1593.
Scheuba C., Kaserer K, Weinhäusl A, Pandev R., Kaider A., Passler C., Prager G., Vierhapper H., Haas O.A., Niederle B. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin test. Surgery 1999, 126: 1089–1096.
Wion-Barbot N., Schuffenecker I., Niccoli P., Conte-Devolx B., Lecomte J., Houdent C., Bigorgne J.C., Modigliani E. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. Ann. Endocrinol. (Paris) 1997, 58: 302–308.
Thompson R.S., Jackson A.P., Langlois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects: incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme. Clin. Chem. 1986, 32: 476–481.
Vaidya H.C., Beatty B.G. Eliminating interference from heterophilic antibodies in a two-site immunoassay for creatine kinase MB by using F(ab’)2 conjugate and polyclonal mouse IgG. Clin. Chem. 1992, 38: 1737–1742.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tommasi, M., Brocchi, A., Cappellini, A. et al. False serum calcitonin high levels using a non-competitive two-site IRMA. J Endocrinol Invest 24, 356–360 (2001). https://doi.org/10.1007/BF03343873
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343873